Rigel
BMS in $1.5 billion immuno-oncology expansion
February 24, 2015Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Rigel, flexus, immuno-oncology
Bristol-Myers Squibb has confirmed two major deals to enhance the company’s standing in the immuno-oncology field. The first agreement sees …
AstraZeneca abandons late-stage RA drug
June 5, 2013Research and Development, Sales and Marketing AstraZeneca, RA, Rigel
AstraZeneca is to exit development of a new rheumatoid arthritis drug, after Phase III trials produced disappointing results.The Anglo-Swedish firm …
Pfizer drops early-stage asthma candidate
May 11, 2011Research and Development Pfizer, Rigel, asthma
Pfizer has returned the rights to a phase I asthma candidate to Rigel Pharmaceuticals. San Francisco-based Rigel says Pfizer is …
Solid results for AstraZeneca’s oral RA drug
September 23, 2010Research and Development AstraZeneca, Rigel, fostamatinib, rheumatoid arthritis
AstraZeneca’s new oral treatment for rheumatoid arthritis has produced solid results in a phase II trial. Fostamatinib is the first …
AstraZeneca signs deal with Rigel on RA treatment
February 17, 2010Research and Development AZ, Rigel, rheumatoid arthritis
AstraZeneca is looking to enter the lucrative rheumatoid arthritis market by in-licensing a phase II treatment.The global market for rheumatoid …
